The study followed the World Health Organization (WHO) in vivo test protocol for monitoring antimalarial drug resistance. Since early relapses can occur after 17 days post-primary blood infection, for the primary blood infection clearance, patients were followed up for ≈Day 28 and from one month and up to 12 months to monitor relapse elimination. When required, a flexible schedule was implemented to facilitate patients' follow up and minimized patient lost as suggested by others (Ruebush et al., 2003).